Vascular Closure Device

DEVICE3 trials

Sponsors

Cordis US Corp., Taewoong Medical Co., Ltd., Shanghai 10th People's Hospital

Conditions

Angioplasty, Transluminal, Percutaneous CoronaryCoronary ArteriosclerosisPeripheral ArteriosclerosisThe Patients Who Needed Hemostasis at the Puncture Site of Common Femoral Artety(CFA) Caused by Femoral Angiogram or Intervention After the Catheter RemovalVascular Access Complications

Phase 3

Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device

CompletedNCT00345631

Cordis US Corp.Angioplasty, Transluminal, Percutaneous Coronary, Coronary Arteriosclerosis, Peripheral Arteriosclerosis

Start: 2007-02-28End: 2007-09-30Updated: 2012-06-01

Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable VCD and Perclose® ProGlide SMC System

TerminatedNCT01597570

Taewoong Medical Co., Ltd.The Patients Who Needed Hemostasis at the Puncture Site of Common Femoral Artety(CFA) Caused by Femoral Angiogram or Intervention After the Catheter Removal

Start: 2012-05-31End: 2012-12-10Updated: 2017-07-25

Unknown Phase

Application of Vascular Closure Device in Transvenous Cardiac Intervention

Shanghai 10th People's HospitalVascular Access Complications

Start: 2022-09-30End: 2023-12-01Target: 160Updated: 2022-09-27

Related Papers

A randomized comparison of a novel bioabsorbable vascular closure device versus manual compression in the achievement of hemostasis after percutaneous femoral procedures: the ECLIPSE (Ensure's Vascular Closure Device Speeds Hemostasis Trial).

2009-08-0166 citations